Physician profile
Eric P Trawick
NPI 1699979187
$53,546.06
in general payments reported to CMS, 2019-2025
33 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $441 · 2021: $1,702 · 2022: $3,373 · 2023: $1,940 · 2024: $806 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,722 · Consulting Fee: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,721.72 |
| Consulting Fee | $901.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $21,535.32 | 2019 | |
| Reshape Lifesciences INC. | $15,916.50 | 2019 | |
| Olympus America INC. | $6,749.54 | 2019-2024 | Single Use Electrosurgical Hemostatic Forceps |
| Olympus Corporation | $3,218.76 | 2022-2023 | |
| Abbvie INC. | $2,693.16 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $625.20 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $532.15 | 2021-2024 | Zeposia |
| Pfizer INC. | $364.42 | 2019-2025 | |
| Gilead Sciences, INC. | $309.83 | 2022-2025 | |
| Boston Scientific Corporation | $284.70 | 2019-2022 | |
| Medtronic, INC. | $250.53 | 2021-2023 | Pillcam |
| Genzyme Corporation | $159.13 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.72 | 2019-2025 | Fruzaqla, Entyvio |
| Merck Sharp & Dohme LLC | $115.81 | 2021-2024 | Keytruda, Lynparza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $68.28 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $50.32 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.30 | 2023-2024 | Dupixent |
| Daiichi Sankyo INC. | $47.59 | 2021-2022 | |
| Allergan, INC. | $41.68 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $40.75 | 2025 | Onivyde, Somatuline Depot |
| Jazz Pharmaceuticals INC. | $30.92 | 2025 | |
| Genentech USA, INC. | $25.93 | 2024 | Itovebi |
| Covidien LP | $20.99 | 2019 | |
| Conmed Corporation | $19.72 | 2020 | |
| Amgen INC. | $17.43 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.51 | 2019 | |
| Enterra Medical, INC. | $14.82 | 2022 | |
| Ucb, INC. | $14.03 | 2019 | |
| Qol Medical, LLC | $12.47 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.97 | 2019 | |
| Braintree Laboratories, INC. | $11.92 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Trawick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.